Genmab Management
Management criteria checks 4/4
Genmab's CEO is Jan G.J. de Winkel, appointed in Jun 2010, has a tenure of 13.92 years. total yearly compensation is DKK44.30M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth $176.56M. The average tenure of the management team and the board of directors is 7.3 years and 7.2 years respectively.
Key information
Jan G.J. de Winkel
Chief executive officer
kr.44.3m
Total compensation
CEO salary percentage | 20.8% |
CEO tenure | 13.9yrs |
CEO ownership | 0.9% |
Management average tenure | 7.3yrs |
Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Genmab: A Complicated Tale
May 01Genmab Acquires A Missing Piece For Its Pipeline
Apr 16Genmab: Recent Updates Support The Growth Narrative
Feb 21Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)
Jan 23Genmab: 3 Trends To Track For A Strong 2024 And Beyond
Jan 12Genmab reports Q3 worldwide sales of $2.05B for Darzalex
Oct 18Genmab improves FY 2022 guidance
Aug 08Genmab reports Q2 worldwide net sales of DARZALEX $1.99B
Jul 19Genmab: A Royalty Powerhouse With A Strong Pipeline
Jun 28Genmab: Looking For Growth At A Reasonable Price
Jun 10Genmab: A Biotech Company On The Rise
Mar 12Genmab: Ready For More Growth In 2022
Dec 23Genmab: Monoclonal Antibody Experts, Low Risk Business Model
Aug 18CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | kr.5b |
Dec 31 2023 | kr.44m | kr.9m | kr.4b |
Sep 30 2023 | n/a | n/a | kr.4b |
Jun 30 2023 | n/a | n/a | kr.5b |
Mar 31 2023 | n/a | n/a | kr.5b |
Dec 31 2022 | kr.42m | kr.9m | kr.5b |
Sep 30 2022 | n/a | n/a | kr.6b |
Jun 30 2022 | n/a | n/a | kr.4b |
Mar 31 2022 | n/a | n/a | kr.2b |
Dec 31 2021 | kr.38m | kr.8m | kr.3b |
Sep 30 2021 | n/a | n/a | kr.3b |
Jun 30 2021 | n/a | n/a | kr.3b |
Mar 31 2021 | n/a | n/a | kr.6b |
Dec 31 2020 | kr.37m | kr.7m | kr.5b |
Sep 30 2020 | n/a | n/a | kr.6b |
Jun 30 2020 | n/a | n/a | kr.6b |
Mar 31 2020 | n/a | n/a | kr.2b |
Dec 31 2019 | kr.35m | kr.7m | kr.2b |
Sep 30 2019 | n/a | n/a | kr.2b |
Jun 30 2019 | n/a | n/a | kr.1b |
Mar 31 2019 | n/a | n/a | kr.1b |
Dec 31 2018 | kr.28m | kr.7m | kr.1b |
Sep 30 2018 | n/a | n/a | kr.1b |
Jun 30 2018 | n/a | n/a | kr.1b |
Mar 31 2018 | n/a | n/a | kr.1b |
Dec 31 2017 | kr.27m | kr.7m | kr.1b |
Compensation vs Market: Jan G.J.'s total compensation ($USD6.45M) is below average for companies of similar size in the US market ($USD13.58M).
Compensation vs Earnings: Jan G.J.'s compensation has been consistent with company performance over the past year.
CEO
Jan G.J. de Winkel (62 yo)
13.9yrs
Tenure
kr.44,300,000
Compensation
Dr. Jan G.J. van de Winkel, Ph.D. is Independent Director of HOOKIPA Pharma Inc. from 2023 and serves as Chairman of the Board since 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital M...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 13.9yrs | kr.44.30m | 0.94% DKK 176.6m | |
Executive VP & CFO | 4.2yrs | kr.19.60m | 0.011% DKK 2.0m | |
Executive VP & COO | 4.2yrs | kr.21.80m | 0.0045% DKK 839.1k | |
Executive VP & Chief Legal Officer | 14.3yrs | kr.10.10m | no data | |
Executive VP & Chief People Officer | no data | kr.13.20m | no data | |
Executive VP & Chief Strategy Officer | 10.3yrs | kr.8.90m | no data | |
Senior Director of Clinical Operations & Non-Independent Director | no data | kr.800.00k | 0.00060% DKK 112.9k | |
Executive VP & Chief Development Officer | 7.3yrs | kr.21.70m | 0.014% DKK 2.5m | |
Executive VP | 3.2yrs | kr.19.80m | 0.0048% DKK 897.5k | |
Senior Director | no data | kr.1.10m | 0.00081% DKK 152.4k | |
Senior Director of Finance Japan & Non-Independent Director | no data | kr.800.00k | 0.00013% DKK 24.5k | |
Senior Director | no data | no data | no data |
7.3yrs
Average Tenure
50yo
Average Age
Experienced Management: GMAB's management team is seasoned and experienced (7.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Senior Director of Clinical Operations & Non-Independent Director | 2.3yrs | kr.800.00k | 0.00060% DKK 112.9k | |
Senior Director | 5.2yrs | kr.1.10m | 0.00081% DKK 152.4k | |
Senior Director of Finance Japan & Non-Independent Director | 2.3yrs | kr.800.00k | 0.00013% DKK 24.5k | |
Non-Independent Director | 20.5yrs | kr.1.70m | 0.014% DKK 2.7m | |
Independent Director | 2.2yrs | kr.1.90m | no data | |
Independent Chairman of the Board | 7.2yrs | kr.2.80m | 0.0089% DKK 1.7m | |
Independent Director | 7.2yrs | kr.1.50m | 0.0052% DKK 980.2k | |
Independent Deputy Chairman | 9.3yrs | kr.2.10m | 0.0075% DKK 1.4m | |
Independent Director | 9.3yrs | kr.1.50m | 0.0032% DKK 609.6k |
7.2yrs
Average Tenure
58yo
Average Age
Experienced Board: GMAB's board of directors are considered experienced (7.2 years average tenure).